Globus Medical (GMED) Q4 2025 earnings review
Accelerating Base Business and a Dramatic Robotics Rebound
Globus Medical crushed Q4 expectations, capping a volatile year with broad-based acceleration. The real story isn't just the 26% total revenue growth—it's the 10.6% growth in the base business, proving the NuVasive integration is finally yielding above-market share gains. Furthermore, Enabling Technologies—the robotics and imaging segment that dragged down growth all year—staged a massive 19% YoY reversal. Add in aggressive margin expansion that drove Non-GAAP EPS up 52%, and management's raised 2026 profit guidance looks highly credible.
🐂 Bull Case
After three quarters of contraction due to elongated hospital spending cycles, the Enabling Technologies segment surged 19% in Q4, re-establishing a critical growth vector.
The core US Spine business accelerated to 10% YoY growth in Q4. Sustained competitive sales rep hiring is successfully translating into above-market market share gains.
🐻 Bear Case
Despite historical Q4 seasonality in the MedTech sector, sequential revenue for the newly acquired Nevro business stalled, moving only from $99.3M in Q3 to $99.7M in Q4.
The gap between GAAP ($1.03) and Non-GAAP EPS ($1.28) remains wide. Q4 required a $13.4M litigation provision and $17.9M in M&A costs, masking true operational cash flow generation.
⚖️ Verdict: 🟢
Bullish. Management fixed the capital equipment sales pipeline while delivering phenomenal operating leverage and seamlessly raising FY26 EPS guidance.
Key Themes
Enabling Technologies Rockets Back to Life
After plunging 31% in Q1 and struggling through Q3 due to elongated hospital capital cycles, Enabling Technologies rocketed to $55.6M (+19% YoY) in Q4. This confirms management's Q3 strategic pivot toward flexible deal structures (leases and pay-per-click) is working, driving ecosystem placements that will eventually pull through high-margin implant sales.
Base Business Consistently Accelerating
The core engine is humming. Base business (excluding Nevro) grew 10.6% in Q4, tracking a perfect acceleration line from flat in Q1, to 3.3% in Q2, and 7.0% in Q3. U.S. Spine specifically hit 10% growth in the quarter. The 'relentless focus' on hiring top sales talent from competitors is generating compounding returns.
Nevro's Sequential Growth Hits a Wall
The Nevro acquisition integrated smoothly earlier in the year, achieving positive adjusted EBITDA faster than planned. However, top-line sequential growth has flatlined. Q4 revenue of $99.7M barely budged from Q3's $99.3M. In a medical device industry that typically benefits from strong Q4 seasonality (as patients exhaust deductibles), this lack of sequential bump raises questions about underlying demand in the spinal cord stimulation market.
Margin Expansion Through Synergy Capture
Operating leverage was the star of 2025. By shedding redundant costs from NuVasive and aggressively restructuring Nevro, Globus expanded full-year Adjusted Gross Profit to 68.1% (up from 67.4%) and dropped heavy volume to the bottom line. Q4 GAAP net income climbed 430% YoY, proving that synergy targets were not just spreadsheet math.
Other KPIs
Massive cash generation, up from $405.2M in 2024. Q4 alone delivered $202.4M in Free Cash Flow. This war chest allowed the company to easily absorb the $250M Nevro acquisition, complete over $255M in share repurchases, and repay $450M in convertible debt earlier in the year—all while leaving $526M in cash on the balance sheet.
Accelerating. Grew 14.2% on a constant currency basis, marking a solid step up from the ~13.5% CC growth seen in Q3. This confirms management's thesis that deeper penetration in EMEA markets is gaining traction.
Guidance
Stable. The $3.20B midpoint implies ~8.9% YoY growth. While this mathematically decelerates from 2025's M&A-inflated 16.7% growth, it represents a clean, organic-like baseline now that NuVasive and Nevro are annualized. This target reflects solid, above-market industry expectations.
Accelerating operating leverage. Management raised the bottom end of this range (previously $4.30). The $4.45 midpoint represents ~11.8% YoY growth over 2025's $3.98. Profit is guided to grow faster than revenue, signaling immense confidence in ongoing synergy capture and Nevro margin improvements.
Key Questions
Nevro Seasonality
Nevro revenue was completely flat sequentially ($99.3M to $99.7M) despite typical Q4 MedTech seasonality. What drove this stagnation, and what organic growth rate is assumed for Nevro in the FY26 guidance?
Capital Sales Mix
Enabling Technologies posted a fantastic 19% recovery. How much of this was driven by outright cash sales versus the new flexible capital lease structures introduced in Q3, and how does this affect near-term revenue recognition?
Path to Clean GAAP Earnings
With the NuVasive integration in the rearview mirror and Nevro maturing, when does the company expect M&A-related costs and restructuring charges to normalize so GAAP and Non-GAAP EPS can converge?